Efavirenz Mannich bases: Synthesis, anti-HIV and antitubercular activities

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 1, 2009, Pages 1-5

  Sriram, Dharmarajan ^a   Banerjee, Debjani ^a   Yogeeswari, Perumal ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Anti HIV activity; Antitubercular activity; Efavirenz; Mannich bases

Indexed keywords

6 CHLORO 4 (2 CYCLOPROPYLETHYNYL) 4 (TRIFLUOROMETHYL) 1 [(4 PHENYLPIPERAZIN 1 YL)METHYL] 1H BENZO[D][1,3]OXAZIN 2(4H) ONE; 6 CHLORO 4 (2 CYCLOPROPYLETHYNYL) 4 (TRIFLUOROMETHYL) 1 [[4 (4 METHOXYPHENYL)PIPERAZIN 1 YL]METHYL] 1H BENZO[D][1,3]OXAZIN 2(4H) ONE; 7 [4 [[ 6 CHLORO 4 (2 CYCLOPROPYLETHYNYL) 4 (TRIFLUOROMETHYL) 2 OXO 2H BENZO[D] [1,3]OXAZIN 1 (4H) YL]METHYL] 3 METHYLPIPERAZIN 1 YL] 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 7 [4 [[ 6 CHLORO 4 (2 CYCLOPROPYLETHYNYL) 4 (TRIFLUOROMETHYL) 2 OXO 2H BENZO[D] [1,3]OXAZIN 1 (4H) YL]METHYL] 3 METHYLPIPERAZIN 1 YL] 6,8 DIFLUORO 1 ETHYL 1,4 DIHYDRO 4OXOQUINOLINE 3 CARBOXYLIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EFAVIRENZ; FORMALDEHYDE; PIPERAZINE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; MANNICH REACTION; MICROWAVE IRRADIATION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; VIRUS INHIBITION;

ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; FORMALDEHYDE; MANNICH BASES; MICROBIAL SENSITIVITY TESTS; PIPERAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

MYCOBACTERIUM TUBERCULOSIS;

EID: 58949093749     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360701404159     Document Type: Article

References (19)

1. Broder, S. and Gallo, RC (1984) A pathogenic retrovirus (HTLV-III) linked to AIDS. N Engl J Med, 311, pp. 1292-1297.
2. Bowen, DL, Hane, HC and Fauci, AC (1985) Immunopathogenesis of the acquired immunodeficiency syndrome. Ann Intern Med, 163, pp. 704-709.
3. Dye, C., Scheele, S., Dolin, P., Pathania, V. and Raviglione, MC (1999) Consensus statement. Global burden of tuberculosis: Estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA, 282, pp. 677-686.
4. Selwyn, PA, Hartel, D., Wasserman, W. and Drucker, E. (1989) Impact of the AIDS epidemic on morbidity and mortality among intravenous drug users in a New York City methadone maintenance program. Am J Public Health, 79, pp. 1358-1362.
5. Daley, CL, Small, PM and Schecter, GF (1992) An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med, 326, pp. 231-235.
6. Sriram, D. and Yogeeswari, P. (2003) Towards the design and development of agents with broad spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Curr Med Chem, 10, pp. 1689-1695.
7. Sriram, D., Bal, TR and Yogeeswari, P. (2004) Design, synthesis and biological evaluation of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. Bioorg Chem, 12, pp. 5865-5873.
8. Sriram, D., Yogeeeswari, P., Srichakravarthy, N. and Bal, TR (2004) Synthesis of stavudine amino acid ester prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Bioorg Med Chem Lett, 14, pp. 1085-1087.
9. Sriram, D., Yogeeswari, P. and Gopal, G. (2005) Synthesis, anti-HIV and antitubercular activities of lamivudine prodrugs. Eur J Med Chem, 40, pp. 1373-1376.
10. Sriram, D., Srichakravarthy, N., Bal, TR and Yogeeswari, P. (2005) Synthesis of zidovudine prodrugs with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Biomed Pharmacother, 59, pp. 452-455.
11. Sriram, D., Srichakravarthy, N., Bal, TR and Yogeeswari, P. (2005) Nevirapine derivatives with broad-spectrum chemotherapeutic properties for the effective treatment of HIV/AIDS. Biomed Pharmacother, 59, pp. 456-459.
12. Sriram, D., Yogeeswari, P., Myneedu, NS and Saraswat, V. (2006) Abacavir prodrugs: Microwave-assisted synthesis and their evaluation of anti-HIV activities. Bioorg Med Chem, 16, pp. 2127-2129.
13. Sriram, D., Bal, TR and Yogeeswari, P. (2005) Aminopyrimidinimino isatin analogues: Design of novel non- nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties. Med Chem, 20, pp. 565-577.
14. National Committee for Clinical Laboratory Standards (1990) Antimycobacterial susceptibility testing. Proposed standard M24-P, National Committee for Clinical Laboratory Standards, Villanova, Pa
15. Agarwal, SK, Gogu, SR, Rangan, SRS and Agrawal, KC (1990) Synthesis and biological evaluation of prodrugs of zidovudine. J Med Chem, 33, pp. 1505-1509.
16. Young, SD, Britcher, SF, Tran, LO, Payne, LS, Lumma, WC, Lyle, TA, Huff, JR, Anderson, PS, Olsenn, DB, Carroll, SS, Pettibone, DJ, O'Brien, JA, Ball, RG, Balani, SK, Lin, JH, Chen, IW, Schleif, WA, Sardana, VV, Long, WJ, Brynes, VW and Emini, EA (1995) L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother, 39, pp. 2602-2605.
17. Patel, M., Ko, SS, McHugh, RJ, Markwalder, JA, Srivastava, AS, Cordova, BC, Klabe, RM, Erickson-Viitanen, S., Trainor, GL and Seit, SP (1999) Synthesis and evaluation of analogs of Efavirenz (SUSTIVA) as HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem Lett, 9, pp. 2805-2810.
18. Yogeeswari, P., Sriram, D., Kavya, R. and Tiwari, S. (2005) Synthesis and in-vitro cytotoxicity evaluation of gatifloxacin Mannich bases. Biomed Pharmacother, 59, pp. 501-510.
19. Sriram, D., Yogeeswari, P., Basha, SJ, Radha, D. and Nagaraja, V. (2005) Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg Med Chem, 13, pp. 5774-5778.